Product image of Isoprotrace (Gozetotide) supplied by GNH India

Isoprotrace

Active Ingredient:
Gozetotide
Origin:
EU

Isoprotrace (Gozetotide)

Gozetotide, the active ingredient in Isoprotrace, is a drug presented as an intravenous formulation for infusion use. It is currently under clinical investigation and has not been assigned a specific therapeutic class, with its precise indications still being evaluated in research settings.

GNH India supplies Isoprotrace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution, ensuring product integrity throughout the supply chain.

Manufacturer / TM Owner

Billev Pharma Aps

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Isoprotrace (Gozetotide) currently has no publicly disclosed therapeutic indications.

  • Clinical research: Participation in early‑phase trials to determine safety and efficacy.
  • Pre‑clinical studies: Ongoing laboratory investigations to identify potential disease targets.
  • Regulatory review: Awaiting assessment by health authorities for approved indications.

How It Works

  • The precise mechanism of action of Gozetotide has not been publicly disclosed. Available information suggests it may interact with cellular pathways involved in immune regulation, but detailed target receptors or molecular effects remain under investigation. Further pharmacodynamic studies are required to elucidate its binding affinity, downstream signaling cascades, and potential impact on disease processes. Understanding these interactions will inform its clinical development and therapeutic positioning.

Side Effects

No specific adverse effect profile has been publicly disclosed for Gozetotide. Reported observations from early clinical studies include:

Common Side Effects

  • Infusion‑related reactions: mild fever, chills, or flushing.
  • Nausea: occasional mild nausea.
  • Headache: transient headache reported.

Serious or Rare Side Effects

  • Anaphylaxis: rare severe allergic reaction requiring immediate medical attention.
  • Severe hypotension: occasional drop in blood pressure during infusion.

Precautions & Warnings

When handling Isoprotrace, consider the following precautions:

  • Patient assessment: evaluate baseline vital signs before infusion.
  • Allergy screening: confirm no known hypersensitivity to formulation components.
  • Monitoring: observe patient during and after infusion for adverse reactions.
  • Concomitant therapy: review other immunomodulatory agents for additive risk.
  • Pregnancy and lactation: safety not established; avoid use unless benefits outweigh risks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Potential drug interactions for Isoprotrace are limited to theoretical considerations based on its class:

Major Interactions (Avoid)

  • Live vaccines: concurrent administration may increase risk of infection.
  • Strong immunosuppressants: may diminish therapeutic effect.

Moderate Interactions (Monitor Closely)

  • CYP450 substrates: potential alteration of metabolism, monitor plasma levels.
  • Anticoagulants: possible increased bleeding risk, monitor coagulation parameters.
  • Diuretics: monitor electrolyte balance during infusion.

Frequently Asked Questions

Isoprotrace is an investigational intravenous medication that contains the active ingredient Gozetotide. It is currently being studied in clinical trials to explore potential therapeutic applications, but it has not received regulatory approval for any specific indication.

The exact mechanism of Gozetotide has not been publicly disclosed. Preliminary data suggest it may interact with immune‑related cellular pathways, potentially modulating immune responses, but detailed targets and downstream effects are still under investigation.

Dosing for Isoprotrace is determined by the prescribing clinician based on the specific clinical trial protocol or investigational plan. No standardized dosing regimen is publicly available, and the prescriber will set the appropriate dose for each patient.

Safety of Gozetotide during pregnancy or lactation has not been established. It should be avoided unless the potential benefit to the mother clearly outweighs any possible risk to the fetus or infant, and only under specialist guidance.

To order Isoprotrace, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Because Isoprotrace is still investigational and has no approved therapeutic class, direct comparisons with established drugs are limited. Ongoing studies aim to define its efficacy and safety relative to existing treatments in the same disease areas under investigation.

Isoprotrace should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Maintain the cold‑chain during transport and keep the product in its original packaging until ready for use.

Isoprotrace is administered as an intravenous infusion by a qualified healthcare professional. The infusion is given in a controlled clinical setting, with appropriate monitoring of vital signs before, during, and after the administration.

The most serious adverse reactions reported in early studies include anaphylaxis and severe hypotension during infusion. Patients should be closely monitored for signs of allergic reaction, sudden drops in blood pressure, and other acute events.

Isoprotrace should not be used in patients with known hypersensitivity to any component of the formulation, in those with uncontrolled severe cardiovascular disease, or in individuals receiving live vaccines. Use is also contraindicated until safety is established in specific populations.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Gozetotide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT